«
»

Building Health, Restoring Independence

Targacept is...

Targacept, Inc. is a biopharmaceutical company engaged in the development of novel NNR Therapeutics™ for the treatment of various diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

Focus on:

Schizophrenia

An estimated 4.7 million people in the world's seven major pharmaceutical markets suffer from schizophrenia.  For a large portion of those patients, negative symptoms and cognitive dysfunction in schizophrenia remain an umet medical need. READ MORE.

Focus on:

Overactive Bladder 

Overactive bladder (OAB) poses a significant reduction in the quality of life for patients who suffer from the disorder.  READ MORE about our development plans for TC-5214 in this indication.

 


 

Latest News

May 7, 2013 || Targacept Reports First Quarter 2013 Financial Results

April 29, 2013 || Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s Disease

April 22, 2013 || Targacept Announces Participation in Upcoming Conferences

April 18, 2013 || Targacept Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619

November 15, 2012 || Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer

View all news »
Targacept Homepage
Targacept, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, psychiatric disorders, nicotinic channel modulator, central nervous system disorders, CNS, schizophrenia, residual phase schizophrenia, residual symptoms, negative symptoms, cognitive dysfunction, Alzheimer’s disease, age associated memory impairment, AAMI, mild cognitive impairment, MCI, cognition, Parkinson’s disease, L-dopa induced dyskinesia, alpha7 modulators, alpha4beta2 modulators, overactive bladder, OAB, TC-5619, TC-5214, TC-1734, AZD3480, AZD1446, TC-6987
Targacept is a biopharmaceutical company engaged in the development of novel NNR Therapeutics for the treatment of various diseases and disorders of the nervous system.